Abstract. Neuroendocrine tumors in the lung fall into four categories: typical carcinoid tumor (TC), atypical carcinoid tumor (AC), large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung carcinoma (SCLC), in ascending order of malignancy. The drs gene was originally isolated as a suppressor against v-src transformation and was shown to induce apoptosis in human cancer cells. The expression of drs was markedly downregulated in various human cancer tissues and cell lines. Furthermore, drs knockout mice showed a tumor-prone phenotype, indicating that drs acts as a tumor suppressor gene in malignant tumor formation. To clarify the role of the drs gene in the development of human pulmonary neuroendocrine tumors, we examined the expression of drs mRNA in tissue specimens from 3 cases of TC, 4 cases of AC, 2 cases of LCNEC, and 11 cases of SCLC by in situ mRNA hybridization. Four cases of normal lung and bronchial epithelia, 8 samples of normal brain tissue, and 2 cases of tumorlets in the lung were also examined. The drs mRNA was definitely expressed in all normal tissues of the lung and brain, and 3 TC and 2 tumorlet tissues. The expression of drs mRNA was also detected in 2 of 2 LCNEC tissues and 3 of 4 AC tissues, although the signals were weak. On the other hand, drs mRNA was not detected in 10 of 11 SCLC tissues. Downregulation of drs mRNA was also observed in 3 of 4 SCLC cell lines that were examined by reverse transcriptasepolymerase chain reaction (RT-PCR). Neither gross deletion nor rearrangement of the drs genome was detected in these cell lines by Southern blot analysis. Our results indicate that the downregulation of drs is correlated with the development of SCLC, a highly malignant pulmonary neuroendocrine tumor.
Introduction
Small-cell lung carcinoma (SCLC) has been reported to show neuronal characteristics including many neuronal markers, neuronal cell adhesion molecules, a neuron-restrictive silencer factor, neurotransmitters, and voltage-gated ion channels, namely, membrane excitability (1) . Lung neuroendocrine tumors include the following tumor types: typical carcinoid tumor (TC), atypical carcinoid tumor (AC), large cell neuroendocrine carcinoma (LCNEC), and small-cell lung carcinoma (2, 3) . The five-year survival rate of patients with these tumors was reported to be 87-100% in TC, 37-71% in AC, 15-45% in LCNEC, and 0-20% in SCLC (3) . Although the five-year survival rate decreases from TC to SCLC, each tumor type is considered to develop independently and not to progress from one type to another. Almost all carcinoid tumors in the lung show few symptoms, and they are rarely resected. Studies of the genetic alterations of proto-oncogenes and tumor suppressor genes, including myc, PTEN, p53, and Rb, in SCLC have been performed (4) (5) (6) . Various genetic changes such as chromosomal loss, mutations, and methylation were also reported for other carcinoid tumors, including TC, AC, and LCNEC (7) (8) (9) (10) (11) (12) . However, analyses of the expression of oncogenes or tumor suppressor genes in pulmonary neuroendocrine tumors covering all four categories have been scarcely reported.
The drs gene was originally isolated as a suppressor of v-src transformation (13, 14) . The expression of drs mRNA has been shown to be markedly downregulated in a variety of human cancer cell lines (15) and malignant tumor tissues, including colon cancer (16, 17) , pulmonary adenocarcinoma (18) , prostatic carcinoma (19) , and adult T-cell leukemia/ lymphoma (20) , suggesting the potential role of this gene as a tumor suppressor. We also found that Drs protein interacted with ASY/Nogo-B, an apoptosis-inducing protein localized in the endoplasmic reticulum, and that ectopic expression of the Drs protein induced apoptosis in human cancer cells without mitochondrial involvement (21) . Furthermore, malignant tumors including T-cell lymphomas, lung adenocarcinomas and hepatomas were generated in ~30% of the drs knockout mice (22) . All these findings indicate that drs is involved in the suppression of malignant tumor formation by promoting apoptosis.
In this study, to clarify the role of the drs gene in the development of neuroendocrine tumors in the lung, we investigated the expression level of drs mRNA in tissue specimens from four categories of human pulmonary neuroendocrine tumors by in situ hybridization and in SCLC cell lines by the reverse transcriptase-polymerase chain reaction (RT-PCR). It is necessary to examine series of all these pulmonary neuroendocrine tumors employing a standardized technique. Our results showed that the downregulation of drs is correlated with the malignancy of pulmonary neuroendocrine tumors, and suggested that drs played a role in the development of SCLC. Cell lines. The human SCLC cell lines used in this study were H69, Lu139, LC22, and REFE-LC-MS. Normal human fibroblasts (HF) were also used as a positive control for the expression of drs mRNA. These cells were cultured in RPMI-1640 medium supplemented with 10% fetal calf serum.
Patients and methods

Patients
In situ mRNA hybridization. Formalin-fixed paraffin-embedded tissues were cut in serial sections of a 3-mm thickness. As a probe, human drs cDNA was cloned into the plasmid, pBluescript II SK(-). The sense and antisense RNA probes were labeled with digoxigenin-11-UTP by in vitro transcription using a commercial kit (Roche-Boehringer-Mannheim, Indianapolis, IN, USA). The labeled riboprobes were then fragmented to ~100 bases in length by alkaline hydrolysis. The sense probe served as a negative control. In situ mRNA hybridization was performed as described previously (16, (18) (19) (20) . The adjacent sections of the paraffin blocks were stained with hematoxylin and eosin (H&E).
RT-PCR.
Reverse transcription was carried out using total RNA (2 μg) from the cell lines. Oligo(dT)-adaptor primers (Invitrogen) were employed for the reverse transcription reaction. The reverse transcription products were amplified through 30 cycles using degenerate primers (0.4 μM), and Takara Ex Taq polymerase (2.5 units). The primer sets employed for PCR to detect human drs mRNA were 5'-TTA AGTGAGCTGTGCAGCCT-3' for the forward primer (pDrsU2) and 5'-TAACAGCACATCAGACGTTGC-3' for the reverse primer (pDrsSR3, which is located in the 3' downstream of the consensus repeat 2 of drs). The primer sets used to detect glyceraldehyde-3-phosphodehydrogenase (GAPDH) were 5'-CTGCAAGGGGCTGATAAGAG-3' for the forward primer and 5'-AGGGGTCAGCCTTGTTTTCT-3' for the reverse primer. Amplicons were separated in 1.5% agarose gel.
Southern blot analysis.
Genomic DNA from the cell lines was digested with restriction enzymes, separated by 1% agarose gel electrophoresis, and transferred to a nylon filter. The filter was then hybridized with a 32 P-labeled probe at 42˚C overnight in hybridizing buffer (50% formamide, 0.6 M sodium chloride, 60 mM sodium citrate, 0.2% SDS, 0.1% bovine serum albumin, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, and 50 μg of herring sperm DNA/ml). The hybridized filter was washed with 15 mM sodium chloride, 1.5 mM sodium citrate, and 0.1% SDS at 55˚C, and then autoradiographed.
Results
To clarify the correlation between the downregulation of drs mRNA and development of neuroendocrine tumors in the lung, we investigated the expression of drs mRNA in tissues of four categories of human neuroendocrine tumors, including TC, AC, LCNEC, and SCLC, by in situ mRNA hybridization. Tissue specimens of 3 cases of TC, 4 cases of AC, 2 cases of LCNEC, and 11 cases of SCLC were prepared from 20 patients. For a comparative study, normal lung, bronchial and neuronal tissues, and pulmonary tumorlets, which are suspected to be noncancerous growths of Kultschitzky cells, were also prepared.
The results of drs mRNA in situ hybridization are summarized in Table I , and representative pictures of the in situ hybridization with sense and antisense probes and H&E staining are shown in Fig. 1 . drs mRNA was definitively expressed in the cytoplasm of normal human brain, lung, and bronchus tissues with antisense probes (Fig. 1a, c , and e, respectively), but was not detected with sense probes (Fig. 1b  and d) . The large pyramidal cells (Fig. 1a) and type I pneumocytes (Fig. 1c) showed distinct signals. The bronchial epithelial cells also exhibited strong signals (Fig. 1e) . In the tissues examined from 2 tumorlets, clear drs-positive signals were detected with antisense probes (Fig. 1f) . In 3 cases of typical carcinoid (TC) tissues, strong signals were detected (Fig. 1g) .
In 4 cases of atypical carcinoid (AC), one case (case 1) showed strong signals and 2 cases (cases 2 and 3) showed weak signals (Fig. 1h) , but the other case (case 4) exhibited no signals (see Table I ). In the two large cell neuroendocrine tumors (LCNEC) examined, drs-positive signals were detected, although one case showed weak signals (Fig. 1i) . In neuroendocrine tumors, including TC, AC, and LCNEC, which showed a relatively high five-year survival rate, drs mRNA was mostly expressed. On the other hand, the expression of drs mRNA was not detected in almost any of the (10/11) small-cell lung carcinoma (SCLC) tissues examined ( Fig. 1j and k) . Only one case (case 1) of SCLC exhibited very weak signals.
To confirm the results of drs mRNA expression in SCLC tissues, we also investigated the expression of drs mRNA in four SCLC cell lines (H69, Lu139, LC22, and REFE-LC-MS) ONCOLOGY REPORTS 21: 1367-1372, 2009 Figure 1 . In situ hybridization analyses of the expression of drs mRNA in human pulmonary neuroendocrine tumors. (a-k) In situ hybridization; a, hippocampus with antisense probe, x200; b, hippocampus with sense probe, x200; c, normal lung (case 1) with antisense probe, x200; d, normal lung (case 1) with sense probe, x200; e, normal bronchus with antisense probe, x200; f, tumorlet (case 2) with antisense probe, x200; g, typical carcinoid tumor (case 1) with antisense probe, x200; h, atypical carcinoid tumor (case 1) with antisense probe, x200; i, LCNEC (case 2) with antisense probe, x200; j, SCLC case (case 4) with antisense probe, x200; k, SCLC (case 11) with antisense probe, x200; (l-p) hematoxylin and eosin (H&E) staining; l, hippocampus, x200; m, tumorlet (case 2), x200; n, typical carcinoid tumor (case 1), x200; o, LCNEC (case 2), x200; p, SCLC (case 4), x200. by RT-PCR. Human fibroblasts (HF) were also used as a positive control. As shown in Fig. 2 , the expression of drs mRNA was not detected in 3 of the 4 SCLC cell lines examined (H69, Lu139, and LC22). Only one cell line, REFE-LC-MS, showed a weak signal compared with the strong signal seen in HF cells. This RT-PCR result was also confirmed by the in situ mRNA hybridization method (data not shown).
To examine the status of the drs genome in these SCLC cell lines, Southern blot hybridization was performed using the same cell lines. As shown in Fig. 3 , no large deletions or rearrangements were detected in the genome of the drs gene in SCLC cell lines whose levels of drs mRNA were markedly reduced (H69, Lu139, and LC22). Our results indicate that the expression of drs mRNA was markedly downregulated in most malignant SCLC tissues and cell lines, suggesting that the downregulation of drs plays a role in the development of SCLC.
Discussion
In the present study, we investigated the expression of the drs tumor suppressor gene in four categories of human pulmonary neuroendocrine tumors, and found that the expression of drs mRNA was markedly downregulated in most SCLC tissues and cell lines among these neuroendocrine tumors. As for other Table I . In situ mRNA hybridization. M  T1N2M0  3A  -3  51  M  T2N0M0  1B  -4  72  M  T1N2M0  3A  -5  71  M  T1N0M0  1A  -6  75  M  T3N3M0  3B  -7  -8  -9  -10  -11 -
categories of neuroendocrine tumors, including TC, AC, and LCNEC, drs mRNA was clearly expressed in most of these tumor tissues, although the expression was weak in some of them, especially in AC and LCNEC tumors.
Considering the malignancy of these four categories of neuroendocrine tumors, as estimated by the five-year survival rate of patients (3), these results suggest that the downregulation of the drs gene is correlated with the malignancy of neuroendocrine tumors, because drs downregulation was most evident in malignant SCLC tumors (five-year survival rate: 0-20%), and drs mRNA was definitely expressed in all cases of TC tumors (five-year survival: 87-100%) examined. Since TC is less malignant and frequently classified as a group containing tumorlets (23), we examined the sum of these two categories. As a result, a significant difference was seen in the ratio of cases with drs mRNA expression between SCLC (1/11) and tumorlet plus TC (5/5) (p=0.0005 by ¯2 examination; p=0.0014 by Fisher's examination).
In AC and LCNEC, which show moderate five-year survival rates (37-71% and 15-45%, respectively), the expression of drs mRNA was relatively weak. As for AC tumors, the level of atypia varied across tumors. This result may reflect the expression level of drs mRNA. The expression of drs mRNA was not correlated with the clinical stage or TNM classification, at least in the neuroendocrine tumors examined. These results are similar to those in our previous in situ hybridization experiments on colon and lung adenocarcinomas (16, 18) . drs mRNA was strongly expressed in colon adenoma with mild atypia, but was downregulated in adenomas with moderate atypia and adenocarcinoma. The downregulation of drs mRNA was also correlated with a poor degree of differentiation and the progression of prostatic carcinoma (19) . The present study showed that the link between drs downregulation and malignancy is also applicable to neuroendocrine tumors, although the latter do not progress.
Originally, the drs gene was found to be downregulated in a rat fibroblast cell line by retroviral oncogenes such as v-src, v-ras, v-sis, and v-mos (13) . Therefore, a possible explanation for the present findings is that the expression of the drs gene is downregulated by the activation of endogenous oncogenes in SCLC. In fact, it has been reported that myc is overexpressed by gene amplification in SCLC (5) . Loss of heterozygosity (LOH) of PTEN, which activates Akt, was also frequently observed in SCLC cell lines (4) . Recently, it was reported that Pyk2 and Src kinase activation plays an essential role in the neuropeptide-induced proliferation of SCLC cells (24) .
Our study revealed differential drs expression in neuroendocrine tumors in the lung, and the loss of drs function in SCLC, suggesting that drs is involved on the development of SCLC. Previously, it has been reported that SCLC derived from bronchial epithelial cells, whereas, typical carcinoid derived from neural crest cells (25) . Therefore, SCLC is suspected to be different from other neuroendocrine tumors. On the other hand, the evidence indicating that low grade neuroendocrine carcinoma (atypical carcinoid) shows intermediate characterictics between SCLC and typical carcinoid was reported (26) . Our results presented herein agreed with these studies. Further investigation, including the detection of small mutations and methylation of the drs genome in SCLC tissues and cell lines, is necessary to clarify the mechanism of the downregulation of drs mRNA in the genesis of SCLC.
